PRESS RELEASES

04.19.2023
Epic Sciences Announces Medicare Coverage for Breast-Cancer Focused ctDNA Gene Panel
Read More
04.14.2023
Epic Sciences RAISES $24m IN SERIES G FINANCING TO CONTINUE FUNDING COMMERCIALIZATION OF DEFINEMBC
Read More
06.01.2022
EPIC SCIENCES RAISES $43M IN FIRST CLOSE OF SERIES F FINANCING TO ADVANCE COMPREHENSIVE PROFILING FOR METASTATIC CANCER PATIENTS
Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $43 million first close of its Series F financing. The company will use the capital from this additional round of private investment to continue to advance its multi-omic platform and expand operations in areas such as single-cell sequencing and data analytics infrastructure. Read More
05.04.2022
Epic Sciences’ DefineMBC™ Test Delivers Comprehensive Liquid Biopsy Results for Metastatic Breast Cancer
Epic Sciences, Inc. has added DefineMBC™, a novel comprehensive blood-based test for characterizing metastatic breast cancer, to its CLIA laboratory menu. Read More
02.24.2022
Epic Sciences And Fulgent Genetics Collaborate To Deliver DefineMBC™ Results For Metastatic Breast Cancer Patients
Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent’s leading CAP/CLIA certified Next Generation Sequencing services with Epic’s best-in-class cell analysis platform as part of Epic’s novel DefineMBC liquid biopsy test. Read More
01.30.2022
Epic Sciences And Biosplice Therapeutics Announce Partnership For Metastatic Cancer Trials
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Epic Sciences, Inc., a leading liquid biopsy diagnostic company, announce they are collaborating to incorporate multi-omic profiling in Biosplice’s clinical oncology programs, including Cirtuvivint (SM08502). Read More
12.16.2021
Epic Sciences Unveils DefineMBC™, A Novel Blood-Based Test Designed To Improve Care For Metastatic Breast Cancer Patients
Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available. Read More
12.15.2021
Epic Sciences Platform Demonstrates Compelling Value of Cell Analysis in Data Presented At San Antonio Breast Cancer Symposium 2021
Epic Sciences, Inc. (Epic)’s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate. Read More
12.15.2021
Epic Sciences Expands Leadership Team to Address Liquid Biopsy Demand
Epic Sciences, Inc., developer of novel diagnostics to personalize and advance the treatment and management of cancer, today announced the appointment of Jason Christiansen as Chief Technology Officer, Mark Aguillard as Vice President/ General Manager of the Oncology Business Unit, and Amara Siva as Vice President of Laboratory Operations. These three new executives bring a combined 60 plus years of experience to the Epic Sciences team. Read More
09.19.2021
Epic Sciences Comprehensive Cancer Profiling Platfom Shows Compelling Value of Cell Analysis in Data Presented At ESMO Congress 2021
Epic Sciences, Inc.’s (Epic) Comprehensive Cancer Profiling™ Platform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate. Read More
02.11.2021
Epic Sciences to Present New Data Demonstrating Expanded Clinical Utility of Circulating Tumor Cell (CTC) Count at 2021 ASCO Genitourinary (GU) Cancers Symposium
Epic Sciences, Inc. announced today it will present two abstracts at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium virtual meeting on February 11 – 13, 2021. The abstracts feature analysis on the prognostic and predictive value of CTC enumeration in men with progressing mCRPC starting a standard-of-care therapy. Read More
11.19.2020
Epic Sciences Enters into Exclusive Licensing Agreement and Collaboration with USC Michelson Center to Advance Next-Generation Liquid Biopsy Technology for Precision Oncology
Epic Sciences, Inc. today announced it has entered into an exclusive license and collaboration agreement with Dr. Peter Kuhn and the USC Michelson Center for Convergent Bioscience. Dr. Kuhn is a founding member of the USC Michelson Center and leads USC’s Convergent Science Institute in Cancer (CSI-Cancer). The collaboration will improve Epic’s platform and enable more precise characterization of rare circulating tumor cells (CTCs), which Epic is developing into liquid-biopsy diagnostics used for characterizing a patient’s cancer to guide treatment decisions. Read More
10.29.2020
Epic Sciences and Predicine Jointly Announce Strategic Partnership to Expand Liquid Biopsy Offerings to Biopharmaceutical Partners
Epic Sciences, Inc. and Predicine, Inc. today announced they have entered into a global strategic partnership to offer biopharmaceutical companies access to both Predicine’s ctDNA-based testing and Epic’s CTC-based testing. Predicine’s lead offering is PredicineATLASÔ, the broadest CLIA-certified ctDNA-based assay that analyzes 600 cancer-related genes, using next generation sequencing. Epic’s CTC-based platform offers testing of AR-V7, AR-N term, PSMA, ER, PR and other phenotypic tests. The combination of both approaches allows pharmaceutical partners engaged in clinical trials to measure both genotypic and phenotypic markers from a single blood draw. Read More
09.14.2020
Epic Sciences Enters into Collaboration with Q2 Solutions to Expand Liquid Biopsy Capabilities
Epic Sciences, Inc. today announced it has entered into a global collaboration with Q2 Solutions®, a leading clinical trial laboratory services organization,to offer Illumina®’s TruSight Oncology 500 liquid biopsy test to Epic’s global biopharmaceutical customers. The addition of TruSight Oncology 500 to Epic’s portfolio of testing capabilities, brings ctDNA analysis to Epic’s CTC-based platform that enumerates and characterizes circulating tumor cells (CTCs). TruSight Oncology 500 enables analysis of circulating tumor DNA (ctDNA) of the full exonic sequence of over 500 genes in key cancer-related pathways, and includes identifying single-nucleotide variants, indels, copy number variants, DNA fusions, microsatellite instability (MSI) and tumor mutational burden (TMB). Read More
05.30.2020
Epic Sciences to Present Multiple Abstracts at ASCO 2020 Highlighting the Importance of CTCs in Liquid Biopsy
Epic Sciences, Inc. today announced that it will present three abstracts at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held from May 29 – June 2, 2020. Epic Sciences will present new data demonstrating the role of circulating tumor cells (CTCs) in cancer prognosis and treatment outcomes. Read More
02.06.2020
Epic Sciences to Present New Data Demonstrating Expanded Clinical Utility of AR-V7 at 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium
Epic Sciences, Inc. announced today it will present two abstracts at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium to be held in San Francisco, February 13 – 15, 2020. The abstracts feature two analyses of the PROPHECY trial cohort. One abstract evaluates the androgen-receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) as a predictor of resistance to anti-androgen therapy. The second abstract reports new data on CTC-based biomarkers of chromosomal instability and small-cell neuroendocrine transformation and their association to resistance to anti-androgen therapy. Read More
12.05.2019
Epic Sciences to Present New Data Showing Feasibility of its Liquid Biopsy Test in Breast Cancer
Epic Sciences, Inc. today announced the presentation of new data demonstrating the feasibility of using its proprietary technology for the detection and characterization of rare cells to guide the treatment of breast cancer. The data to be presented show the use of Epic Sciences’ liquid biopsy test to profile circulating tumor cells (CTCs) based on morphological features, protein marker expression and genomic alterations. Epic Sciences will present the data at the 2019 San Antonio Breast Cancer Symposium held on December 10 – 14, in San Antonio, Texas. Read More
12.03.2019
Epic Sciences Expands Executive Leadership Team - Appoints Joel Smith as Chief Financial Officer & General Counsel
Epic Sciences, Inc. today announced the appointment of Joel Smith as its chief financial officer and general counsel. Mr. Smith joins the company’s impressive roster of industry veterans. “Joel’s appointment comes at a pivotal time for Epic Sciences as we build upon the commercial success of our AR-V7 test and remain highly focused on bringing transformative clinical solutions to new, unmet cancer indications,” said Lloyd Sanders, president and CEO at Epic Sciences. “His legal expertise in the commercialization of medical technologies, coupled with his background in molecular biology and economics, make him well-suited for this role as we expand our suite of functional cell profiling technologies to advance precision medicine for patients and drug developers.” Read More
05.30.2019
Published Study Demonstrates Feasibility of a Blood Test to Predict Disease Progression and Metastasis in Localized Prostate Cancer
Epic Sciences announced the publication of a six-year study demonstrating the clinical applicability of circulating tumor cells (CTCs) to predict prostate cancer progression and metastasis. The study, conducted in collaboration with the University of Michigan utilizing Epic’s CTC technology platform, is published in the Journal of Clinical Oncology Precision Oncology. Read More
05.22.2019
Epic Sciences Appoints New Chief Technology Officer
Epic Sciences announced that it has named Chockalingam “Palani” Palaniappan as its new chief technology officer to help the company advance its Functional Cell Profiling technology to drive global expansion. Read More
05.15.2019
Epic Sciences to Present New Data Identifying Multiple Cancer Biomarkers Associated with Treatment Response in Prostate and Bladder Cancer at ASCO 2019
Epic Sciences, Inc. today announced its poster presentations for the upcoming 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 through June 4 in Chicago, Illinois. Read More
05.13.2019
Epic Sciences Launches New Corporate Branding and Website
Epic Sciences announced the launch of a new brand identity, redesigned logo, tagline and website. The new brand changes reflect Epic Sciences’ evolving product portfolio offerings, diverse customer base and expanding global reach. Read More
04.23.2019
Epic Sciences Receives CE Mark for Liquid Biopsy Test Collection Kit. Enables Expanded Access to the Company’s Portfolio of Tests
Epic Sciences (“Epic”) announced today that it has received a CE mark for its Liquid Biopsy Test Collection Kit, allowing for sale and distribution of the company’s products within the European Economic Area (EEA). This kit is compatible with Epic’s rapidly expanding menu of diagnostic and clinical trial tests, including those for interventional use. Read More
04.22.2019
Epic Sciences Appoints Richard J. Wenstrup, M.D. as Chief Medical Officer
Epic Sciences, Inc. announced today the appointment of Richard J. Wenstrup, M.D. as chief medical officer. In this role, Dr. Wenstrup will lead clinical development, regulatory and medical affairs strategies for the company and be responsible for advancing the company’s clinical research and product development pipeline. Read More
04.03.2019
Epic Sciences Unveils New Liquid Biopsy Test to Predict Sensitivity to PARP Inhibitors in Prostate Cancer Trial
Epic Sciences, Inc. and its research partners today report the use of the company’s new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of drug resistance in patients with metastatic castration-resistant prostate cancer (mCRPC). The assay is being utilized as a selection device in BeiGene, Ltd.’s ongoing Phase 2 clinical trial with its investigational PARP inhibitor (pamiparib) in this patient population (NCT03712930). Read More
03.25.2019
Epic Sciences Appoints Lloyd Sanders as Chief Executive Officer
Epic Sciences, Inc. (Epic) today announced that Lloyd Sanders has joined the company as president and chief executive officer. After serving nearly six years in the role, Murali Prahalad, Ph.D., has stepped down to pursue new opportunities and has been appointed to Epic’s board of directors. Read More
03.21.2019
Epic Sciences to Present New Data at AACR 2019 Demonstrating Expansion of Functional Cell Profiling Technology into New Indications including Breast, Lung and Prostate Cancer
Epic Sciences, Inc. announced today that new data will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2019, in Atlanta, Georgia, March 29 to April 4, 2019. The data from multiple studies and indications demonstrate the feasibility of Epic’s Functional Cell Profiling (FCP) technology to predict patients’ response to cancer immunotherapies and drugs that target DNA damage repair pathways. Read More
03.20.2019
Epic Sciences Announces Completion of New York State Licensure to Provide the Oncotype DX AR-V7 Nucleus Detect Test for Patients with Metastatic Castration-Resistant Prostate Cancer in New York State
Epic Sciences, Inc. (Epic) announced today that the New York State Department of Health has completed licensure to provide the Oncotype DX® AR-V7 Nucleus Detect™ test for patients with metastatic castration-resistant prostate cancer (mCRPC). The Oncotype DX AR-V7 Nucleus Detect test helps determine which patients may benefit from androgen receptor signaling inhibitor (ARSi) therapy and which may benefit from chemotherapy. The Oncotype DX AR-V7 Nucleus Detect test is a circulating tumor cell (CTC)-based, liquid biopsy test that is commercially available in the United States through Epic’s partnership with Genomic Health. Read More
03.13.2019
Large Prospective Trial Validates Detection of AR-V7 Biomarker Using Epic Sciences’ Platform to Predict Treatment Outcomes for Patients with Advanced Prostate Cancer
New data from the PROPHECY trial, published in the Journal of Clinical Oncology, demonstrate that detection of AR-V7 in circulating tumor cells (CTCs) in blood is predictive of whether men with mCRPC have become resistant to androgen-receptor signaling (ARS) inhibitors and have a low chance of benefit from further ARS therapy. Read More
02.11.2019
Epic Sciences to Present at ASCO-GU 2019 New Data Demonstrating Utility of Liquid Biopsy to Optimize Drug Development
Epic Sciences, Inc. (Epic) announced today the presentation of four posters at the 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), held in San Francisco on February 14-16, 2019. Read More
11.28.2018
Epic Sciences to Present Data at SABCS 2018
Epic Sciences, Inc. (Epic) announced today that they will be presenting new data on inter- and intra-patient phenotypic heterogeneity and the use of HER2 and AR expression in metastatic breast cancer circulating tumor cells at the 2018 San Antonio Breast Cancer Symposium (SABCS) from December 4 – 8 in San Antonio, TX. Read More
11.05.2018
Epic Sciences Joins Forces with Canadian Consortium of Investigators to Predict Late Recurrence of Metastatic Breast Cancer
Epic Sciences is collaborating with four major breast cancer centers on a clinical trial to determine if Epic’s blood test can be used to predict which women, who have already been treated for localized breast cancer, are at risk of late recurrence of metastatic breast cancer. Read More
10.28.2018
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castrate Resistant Prostate Cancer, Effective December 10
Medicare coverage supports clinical utility of the Oncotype DX AR-V7 Nucleus Detect test, providing 25,000 Medicare patients with coverage. Read More
09.24.2018
Epic Sciences Announces Publication Showing Blood Test Could Help Select Metastatic Prostate Cancer Patients Who Respond to PSMA-Targeted Therapies
Epic Sciences, in partnership with Memorial Sloan Kettering (MSK), have demonstrated that a liquid biopsy blood test may be used in clinical trials to find patients who are likely to benefit from PSMA-targeted therapies, before treatment is initiated. Read More
09.12.2018
Epic Sciences Announces Completion of $52 Million Series E Financing
Epic Sciences (Epic) announced today that the company has completed a $52 million Series E financing led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian (NYSE: VAR). Read More
09.04.2018
Epic Sciences Appoints Katherine Atkinson as Chief Commercial Officer
Epic Sciences (Epic), the maker of the world’s first predictive test of drug response in prostate cancer, announced the expansion of its leadership team with the appointment of Katherine Atkinson as chief commercial officer. Read More
06.28.2018
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy Read More
05.22.2018
Epic Sciences Presents Single Cell Genomics Data at 10th DIA China Annual Meeting
New data demonstrates the detection of tumor mutational burden and chromosomal instability in single circulating tumor cells to develop cancer diagnostic tests for guiding immuno-oncology clinical development and decision-making. Read More
05.16.2018
Epic Sciences and Its Collaborators to Present New Data at ASCO 2018
New data validates clinical utility of commercially-available Oncotype DX® AR-V7 Nucleus Detect™ test and additional tests under development for predictive medicine Read More
05.11.2018
Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation
At the 2018 AACR annual meeting, Epic Sciences presented data from two studies demonstrating the company’s “No Cell Left Behind” detection platform’s capability to analyze potential markers of response to immuno-oncology (IO) agents, such as checkpoint inhibitors, vaccines, and CAR-T therapies. Read More
03.30.2018
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized Read More
02.08.2018
Epic Sciences to Present Single Cell PSMA Analysis to Provide Insight into Tumor Heterogeneity and Links to Response with Anti-PSMA Therapy
Epic Sciences will be presenting data, in conjunction with Endocyte Inc., on single cell PSMA analysis at ASCO GU on February 8th, 2018. Read More
01.04.2018
Epic Sciences to Present at the 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit.
Epic Sciences is one of six select companies chosen to present Read More
11.30.2017
Epic Sciences launches metastatic breast cancer circulating tumor cell panel.
Epic Sciences, Inc. announces the release of its breast cancer single-cell profiling panel. The Epic breast cancer panel is the most comprehensive breast cancer biomarker panel available for characterization of circulating tumor cells (CTCs) within a blood sample. Read More
11.02.2017
Epic Sciences launches single-cell microsatellite and chromosomal instability genomic analysis.
New capability identifies sub-clonal tumor microsatellite instability in metastatic cancers to understand patient selection for PD-1 inhibitors, PARP inhibitors and combination therapies. Read More
10.13.2017
Liquid biopsy test identifies androgen receptor protein expression in circulating tumor cells in women with metastatic breast cancer.
Epic Sciences along with researchers at the MD Anderson Cancer Center (MDA) have recently published their findings on androgen receptor (AR) protein expression in circulating tumor cells (CTCs) in patients with metastatic breast cancer in PLOS One. The publication, the most comprehensive today in characterizing the AR protein in CTCs of patients with breast cancer, identifies subclonal heterogeneity of AR protein. Read More
09.06.2017
Liquid biopsy tumor heterogeneity test predicts resistance to targeted therapy in metastatic prostate cancer patients.
A blood test measuring the diversity of individual circulating tumor cells correlates with differential survival on chemotherapy vs. targeted hormone therapy in metastatic prostate cancer and offers potential to guide treatment choices in multiple solid tumor cancers. Read More
05.08.2017
Epic Sciences and collaborators publish study on new blood test showing expression of PD-L1 on circulating cells is associated with worse outcomes in lung cancer patients not treated with PD-1 inhibitors.
Investigators from Yale, USC, UC San Diego, and Epic Sciences published findings in Cancer Epidemiology, Biomarkers & Prevention, showing that the presence of PD-L1 protein on circulating cells from newly diagnosed lung cancer patients is prognostic of poor survival when patients are treated with standard of care therapeutics not including PD-1 inhibitors. Read More
04.28.2017
Epic Sciences announces completion of $40 million Series D financing.
Epic Sciences announced today that the company has completed a $40 million Series D financing led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital and VI Ventures also participated in the financing. Read More
01.06.2017
Study from MSK and Epic Sciences shows only nuclear-localized AR-V7 Is predictive of therapy benefit for patients with metastatic prostate cancer.
Investigators from Memorial Sloan Kettering Cancer Center (MSK) and Epic Sciences published findings in European Urology, that only nuclear localization of AR-V7 protein in circulating tumor cells (CTCs) from metastatic castration resistant prostatE cancer (mCRPC) patient blood samples is predictive of therapeutic benefit. Read More
11.16.2016
Epic Sciences validates single CTC sequencing, identifies clonal heterogeneity in metastatic cancer.
Epic Sciences, in collaboration with pharma co-authors, published an analytic validation of their sequencing assay in single circulating tumor cells (CTC) and demonstrated clinical feasibility in metastatic prostate cancer patients (mCRPC). Read More
11.16.2016
Liquid biopsy biomarker identifies patients with improved response to PARP inhibition in metastatic castrate resistant prostate cancer.
Epic Sciences announced findings demonstrating a circulating tumor cell (CTC) biomarker can identify patients with metastatic castrate resistant prostate cancer (mCRPC) who are more likely to respond to treatment with a PARP inhibitor in combination with androgen receptor signaling inhibitors (ARSi) compared to those treated with ARSi alone (overall response rate of 93 percent vs. 22 percent). Read More
11.15.2016
Epic Sciences to present at the Canaccord Genuity Medical Technology & Diagnostics Forum.
Epic Sciences, Inc. a private biotech company that designs and develops predictive tests of therapy response in cancer, announced today that Murali K. Prahalad, Ph.D., chief executive officer, will present at the Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 17, 2016 at 10:20 a.m. EST. The conference will be held at the Westin Grand Central in New York. Read More
10.25.2016
Epic Sciences to contribute to Cancer Moonshot Blood Profiling Atlas.
Epic Sciences will contribute to the Blood Profiling Atlas pilot of the Cancer Moonshot Initiative championed by Vice President Biden and the White House. The Blood Profiling Atlas seeks to create an open database of results from liquid biopsy tests to accelerate the development of safe and effective blood profiling diagnostics for patient benefit. Read More
07.06.2016
Genomic Health and Epic Sciences announce strategic collaboration to deliver novel AR-V7 liquid biopsy test.
Genomic Health, Inc. and Epic Sciences, Inc. today announced an exclusive agreement to commercialize Epic Sciences’ novel AR-V7 liquid biopsy test in the United States through Genomic Health’s world-class commercial channel. Read More
06.24.2016
Epic Sciences introduces sensitive HRD liquid biopsy test for PARP inhibitor clinical trials.
Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency (HRD) in individual circulating tumor cells (CTCs). Read More
06.04.2016
Presence of AR-V7 in circulating tumor cells validated as predictive biomarker for advanced prostate cancer treatment by Memorial Sloan Kettering and Epic Sciences.
New Publication: JAMA Oncology 2016. Read More
03.04.2016
Epic Sciences to present at Molecular Medicine Tri-Con 2016.
Epic Sciences, Inc., announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the Molecular Medicine Tri-Con 2016, taking place at the Moscone Convention Center, San Francisco. Read More
01.28.2016
Avera Medical Group and Epic Sciences collaborate on cancer precision medicine clinical trials.
Epic Sciences, Inc. and Avera Medical Group announced today a collaboration on feasibility studies to better understand the effectiveness of personalized cancer treatments as part of novel ovarian and breast cancer clinical trials. Read More
01.11.2016
Epic Sciences receives CAP accreditation.
Epic Sciences announced today that they have received notice of their accreditation from the College of American Pathologists (CAP) for its San Diego laboratory. Read More
01.04.2016
Circulating tumor cells linked with treatment resistance and response in prostate cancer patients.
Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies. Read More
12.11.2015
Epic Sciences enters into 35th pharma collaboration to advance companion diagnostics for new targeted therapeutics.
Epic Sciences, a private biotech company that develops novel diagnostics to personalize and advance the treatment and management of cancer, announced today that it has signed its 35th collaboration agreement with pharmaceutical companies. Read More
12.01.2015
Epic Sciences' chief scientific officer named leading global thinker by Foreign Policy magazine.
Epic Sciences’ Chief Scientific Officer Dena Marrinucci, Ph.D., was named today by Foreign Policy magazine as one of this year’s 100 Leading Global Thinkers. Marrinucci will be honored at a gala in Washington, D.C. this evening. Read More
11.13.2015
Epic Sciences partners with University of Pennsylvania's Abramson Cancer Center on cancer therapy discoveries through liquid biopsy.
Epic Sciences, Inc. announced today a collaboration with the Abramson Cancer Center of the University of Pennsylvania (Penn) on multiple studies to explore biomarkers, identified by analysis of circulating tumor cells (CTCs) at a single cell resolution, that are predictive of response to personalized cancer therapeutics. Read More
11.11.2015
Circulating tumor cells (CTC) in patients' blood detected by Epic Sciences are an "accurate representation" of genetic aberrations found in fresh metastatic tumor samples.
Most men with advanced prostate cancer, whether initially treated through surgical or chemical castration, eventually develop drug-resistant tumors. Monitoring for drug resistant genetic mutations could inform selection of the next line of therapy. A new non-invasive approach developed by Epic Sciences may be as effective at biomarker characterization as invasive surgical biopsies for metastatic castration-resistant prostate cancer (mCRPC) patients. Read More
11.02.2015
Epic Sciences' platform capable of single cell CTC identification sequencing in late stage, metastatic cancer.
After successive cancer therapies, multiple subpopulations of cancer cells arise, each with divergent genetic aberrations that may confer drug resistance or susceptibility. Tissue biopsies may not detect these subpopulations, but a liquid biopsy of blood using Epic Sciences’ no cell left behind® technology may help identify these important tumor cells and characterize how a patient’s tumors have evolved over time. Read More
09.09.2015
Epic Sciences to present at World CDx Boston 2015.
Epic Sciences, Inc. announced today that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the World CDx Boston 2015, taking place at the Hilton Boston Logan Airport, September 8 – 11, 2015. Read More
08.26.2015
Epic Sciences appoints Dave Henderson as chief information officer.
Epic Sciences, Inc. announced today the appointment of Dave Henderson as Epic Sciences’ chief information officer (CIO). Mr. Henderson has more than 20 years of experience in information technologies at companies including Sequenom, Inc., CBS Corporation, and Paramount Pictures Corporation. Read More
08.18.2015
Epic Sciences' Dr. Dena Marrinucci is recognized as an honoree of MIT Technology Review's annual Innovators Under 35 list.
Today, MIT Technology Review revealed its annual list of Innovators Under 35, which includes Epic Sciences’ Dena Marrinucci, Ph.D., who has been recognized for her groundbreaking work in developing and advancing a new technology to unlock the promise of using a simple blood test, called a liquid biopsy, to manage cancer treatments. Read More
08.11.2015
Epic Sciences publication validates unbiased detection of circulating tumor cells (CTC) from a liquid biopsy.
Epic Sciences announced today the publication of its research in the Journal of Circulating Biomarkers validating the company’s no cell left behind™ platform. The data published demonstrate reproducible and linear assay performance in CTC enumeration as well as additional utility in downstream molecular characterization of single CTCs, including protein biomarker analysis and single cell genomics. Read More
07.13.2015
Epic Sciences appoints Dr. Greg Critchfield to board of directors.
Epic Sciences, Inc. a private biotech company that develops diagnostics to personalize the treatment and management of cancer, announced today the appointment of Gregory C. Critchfield, M.D. to Epic Sciences’ board of directors. As current chairman, president and CEO of Sera Prognostics, Inc. and former president of Myriad Genetic Laboratories, Inc., Dr. Critchfield has more than 30 years of experience in the clinical pathology and diagnostics space. Read More
07.07.2015
Epic Sciences expands partnership with LabCorp to provide circulating tumor cell analysis and support oncology clinical trials in Asia.
Epic Sciences announced today an agreement with Laboratory Corporation of America® to provide circulating tumor cell (CTC) technology and support oncology clinical trials in Asia through Covance Drug Development (Covance). Read More
06.01.2015
Epic Sciences expands Silicon Valley Bank credit facility.
Epic Sciences announced today that it has expanded the available credit under its existing credit facility with Silicon Valley Bank (SVB). The availability of additional capital provides Epic Sciences the option to accelerate the expansion of its research capabilities and product development efforts. Read More
05.29.2015
Genetic analysis of single circulating tumor cells shows high intra-patient heterogeneity.
Epic Sciences announced today that the company will present single cell sequencing data, from metastatic castrate resistant prostate cancer patients, at the 2015 annual meeting of the American Society for Clinical Oncology. The study revealed that late stage patients have heterogeneous clonal CTC populations harboring separate genetic alterations. The study, titled “Intra-patient genomic heterogeneity of single circulating tumor cells (CTCs) associated to phenotypic CTC heterogeneity in metastatic castrate resistant prostate cancer (mCRPC),” was conducted in collaboration with clinical investigators at Memorial Sloan Kettering Cancer Center. Read More
05.14.2015
Epic Sciences to present at UPS Global Healthcare Conference.
Epic Sciences, Inc., a private biotech company that designs and develops diagnostics to personalize and advance the treatment and management of cancer, announced today that Michael Rodriguez, chief financial officer, will present at the UBS Global Healthcare Conference on Wednesday, May 20, 2015 at 10:00 a.m. EDT. The conference will be held at the Sheraton New York Times Square Hotel in New York. Read More
04.16.2015
Epic Sciences demonstrates single cell genetic analysis for circulation tumor cells.
Epic Sciences announced today that its no cell left behind™ technology has successfully integrated single cell isolation and downstream genetic analysis of circulating tumor cells (CTCs) to the platform’s capabilities. Data describing next generation sequencing and copy number variation analyses of single prostate cancer cells in a blood sample will be presented during the 2015 annual meeting of the American Association for Cancer Research (AACR), April 18-22, in Philadelphia. Read More
03.09.2015
Epic Sciences and the Prostate Cancer Clinical Trials Consortium collaborate to advance therapeutic development.
Epic Sciences and The Prostate Cancer Clinical Trials Consortium (PCCTC), the leading consortium for Phase 1/2 and Phase 2 clinical trials in prostate cancer, announced today they have entered into a collaboration to apply Epic’s circulating tumor cell (CTC) technology in multiple investigator-initiated clinical trials to advance the development of new prostate cancer treatments. Read More
02.26.2015
EPIC SCIENCES TO PRESENT AT 35TH ANNUAL COWEN AND COMPANY HEALTH CARE CONFERENCE.
Epic Sciences announced today that President and CEO Murali Prahalad, Ph.D. will present at the 35th Annual Cowen and Company Health Care Conference on Wednesday, March 4, 2015 at the Boston Marriott Copley Place Hotel in Boston, Mass. Read More
02.23.2015
Epic Sciences announces presentation of three studies on novel CTC liquid biopsy assays for metastatic prostate cancers and bladder cancers at 2015 SACO GU Cancer Symposium.
Epic Sciences announced today that results from studies in metastatic castration resistant prostate cancer (mCRPC), neuroendocrine prostate cancer (NEPC) and muscle-invasive, metastatic bladder cancers using Epic’s circulating tumor cell (CTC) technology will be presented at the 2015 ASCO Genitourinary Cancers Symposium , February 26 – 28 at Rosen Shingle Creek in Orlando, Fla. Read More
01.26.2015
Epic Sciences to present at Personalized Medicine World Conference 2015 on the use of circulating tumor cells as cancer biomarkers.
Epic Sciences today announced that Murali Prahalad, Ph.D., president and CEO, is scheduled to present at the Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, which is taking place at the Computer History Museum in Mountain View, Calif. on January 26-28, 2015. Read More
01.08.2015
Epic Sciences receives CLIA certification for its cancer diagnostics laboratory.
Epic Sciences announced today that the company has received certification under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the U.S. Department of Health and Human Services’ (HHS) Center for Medicare and Medicaid Services (CMS), the state of California has granted the company’s initial CLIA clinical laboratory license. Read More
11.17.2014
Epic Sciences to present data on a combination CTC and CFDNA assay for molecular targets of non-small cell lung cancer therapies at the 26th EORTC-NCI-AACR Symposium.
Epic Sciences will present data describing the detection of clinically actionable non-small cell lung cancer (NSCLC) biomarkers, including EGFR, KRAS, ALK, MET, RET and ROS1, utilizing both circulating tumor cells (CTC) and circulating free DNA (cfDNA) from a single tube of blood. The poster presentation will take place on November 20 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Read More
11.13.2014
Epic Sciences appoints Toni Wayne as Vice President of Human Resources.
Epic Sciences announced today the appointment of Toni Wayne as vice president of human resources. At Epic, Ms. Wayne will develop best-of-class strategies and processes that facilitate Epic’s continued growth including organizational development, recruitment, training and talent management. Read More
11.12.2014
Epic Sciences to present on characterizing PD-L1 in circulating tumor cells on non-small cell lung cancer patients at the 26th EORTC-NCI-AARC Symposium.
Epic Sciences will present an analysis of PD-L1 protein expression on circulating tumor cells (CTCs) from non-small cell lung cancer (NSCLC) patients. The poster presentation will take place November 19 at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Read More
09.12.2014
Epic Sciences appoints Glen Freiberg as vice president of regulatory affairs and quality assurance.
Epic Sciences announced today the appointment of Glen Paul Freiberg, RAC as vice president of regulatory affairs and quality assurance. At Epic, Mr. Freiberg will advance Epic’s circulating tumor Cell (CTC) technology for 510(K) and PMA approvals. Read More
07.30.2014
Epic Sciences announces Series C financing to advance essential cancer diagnostics for personalized medicine.
Epic Sciences announced today the completion of a $30 million Series C Preferred Stock financing. The financing included new investors RusnanoMedInvest (RMI) and Arcus Ventures, existing investors Domain Associates, Roche Venture Fund, and Pfizer Venture Investments, as well as undisclosed individual investors. Read More
07.30.2014
Epic Sciences appoints Greg Lucier as chairman of the board of directors.
Epic Sciences announced today the appoint of Gregory T. Lucier as chairman of Epic’s board of directors. Mr. Lucier was previously chairman and CEO of Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic’s board of directors to provide expertise as Epic commercializes its circulating rare cell analysis platform with special focus on the development of products and services to detect circulating tumor cells (CTCs) in cancer. Read More
05.05.2014
Epic Sciences selected to present at Cavendish Global Health Impact Forum.
Epic Sciences, developer of novel diagnostics to personalize and advance the treatment and management of cancer, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 New York, NY. The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. Read More
04.08.2014
Epic sciences appoints Pascal Bamford, Ph.D., as vice president of product development.
Epic Sciences announced today the appointment of Pascal Bamford, Ph.D. as vice president of product development. Dr. Bamford has more than 15 years of experience in developing complex, automated diagnostic systems for digital pathology. Prior to joining Epic Sciences, Dr. Bamford served as senior project leader for Advanced Staining Assays at Ventana Medical Systems, Inc., a member of the Roche Group. Dr. Bamford is recognized as a creative innovator and project leader with a successful track record of translating new technologies into high-impact products. Read More
01.29.2014
Epic Sciences partners with LabCorp to accelerate European clinical sample processing CTC technology.
Epic Sciences announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp) to expedite sample processing for Epic’s circulating tumor cell (CTC) technology to support European clinical trials. Read More
01.29.2014
Epic Sciences and collaborators to present six novel abstracts at ASCO GU addressing the clinical applicability of Epic's CTC technology in prostate cancer.
Epic Sciences, in collaboration with the company’s academic and pharmaceutical partners including Memorial Sloan Kettering Cancer Center, Institute of Cancer Research, Weill Cornell Medical College, University of Michigan, and Progenics Pharmaceuticals, will present six novel abstracts at the American Society of Clinical Oncology Genitourinary (ASCO GU) conference, taking place January 30 to February 1 in San Francisco. Read More
02.12.2013
Epic Sciences' research in prostate cancer presented at the 2013 ASCO Genitourinary Cancers Symposium.
Epic Sciences, a private biotech company that develops breakthrough cancer diagnostics, announced the presentation of a research poster at the 2013 Genitourinary Cancers Symposium taking place February 14 to 16 in Orlando, Fla. The symposium presents the latest research in genitourinary cancers and is sponsored by three leading medical specialty societies: American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO). Read More
01.24.2013
Epic Sciences awarded a phase II SBIR contract from NCI/NIH to develop a lung cancer diagnostic blood test.
Epic Sciences, a private biotech company that develops breakthrough cancer diagnostics, announced receipt of a Phase II contract from the Small Business Innovation Research (SBIR) program supported by the National Cancer Institute (NCI) and the National Institutes of Health (NIH). The contract will fund the further development of an assay to identify and characterize circulating tumor cells (CTCs) in lung cancer patients. The results of this contract are expected to provide a basis for the development of new cancer diagnostic products. Read More
08.15.2012
Epic Sciences announces six pharma circulating tumor cell collaborations.
Epic Sciences, a privately held cancer diagnostics company, announced today that it has established collaborations with six pharmaceutical partners employing Epic’s proprietary Circulating Tumor Cell (“CTC”) technology. The partners include two of the top four pharmaceutical companies worldwide. In total, the collaborations include 12 clinical trials involving over 40 distinct projects measuring 18 different protein or genomic tumor markers on CTCs. The clinical trials include sites in the US, Europe and Asia with over 1500 patients and 2500 clinical samples in prostate, lung, breast, pancreatic and ovarian cancers. Read More